Can patients with indolent lymphoma take Zanubrutinib?

Zanubrutinib (Zanubrutinib) is a BTK (brutinib kinase) inhibitor that is widely used to treat B-cell lymphoma and chronic lymphocytic leukemia. However, the appropriateness of zanubrutinib for the treatment of indolent lymphoma needs to be determined on a case-by-case basis. Indolent lymphoma is a very rare subtype of B-cell lymphoma that may respond differently to treatment. Due to the special nature of indolent lymphoma, there is still a lack of sufficient clinical data on the efficacy of zanubrutinib in the treatment of this disease. When choosing treatment for indolent lymphoma, it is best to consult with a professional physician or oncologist. They will be able to assess specific conditions and provide treatment recommendations based on the latest clinical research and guidelines.